Clinical trials: Ovarian
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer
This phase I trial is studying how well ipilimumab works after allogeneic stem cell transplant in treating patients with persistent or progressive cancer.
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Trial name
- NCT00060372
- Testing
- ipilimumab, therapeutic allogeneic lymphocytes
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Ovulation Disorder, Ovarian Cysts
The Role of Estrogen in Luteinizing Hormone Surge and Ovulation
The purpose of the study is to establish that sustained estrogen levels are the driving force for the LH surge, and are thereby necessary for ovulation to occur.
- Trial name
- NCT01999569
- Testing
- Letrozole
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- NEXUS-01 (NCT06465069)
- Testing
- LY4052031, Pembrolizumab
- Where
- 39 sites in United States, Australia and 6 more
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Polycystic Ovary Syndrome
Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment
The aim of this double-blinded, three-armed randomized controlled trial (RCT) is to evaluate the effects of a 6 months treatment with inositol alone or inositol associated with alpha-lipoic acid in women with polycystic ovary…
- Trial name
- IALA (NCT04881851)
- Testing
- Inositol + alpha lipoic acid, Inositol
- Where
- Italy
- Volunteers
- 76 people
- Sponsor
- Universita di Verona
Ovarian Cancer, Malnutrition
Exercise and Nutrition Intervention in Ovarian Cancer
The objective of this multicenter randomized controlled trial is to compare a 6-month exercise and nutrition intervention (intervention group, IG) aimed at maintaining or improving physical functioning and quality of life with…
- Conditions
- Ovarian Cancer, Malnutrition, Muscle Wasting, Fatigue
- Trial name
- BENITA (NCT06250686)
- Testing
- combined exercise and nutrition intervention
- Where
- 7 sites in Germany
- Volunteers
- 185 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Recurrent Platinum-sensitive Ovarian Cancer
Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Evaluation of the best therapeutic index for patients with platinum-sensitive ovarian cancer when treatment with bevacizumab and gemcitabine/carboplatin or with bevacizumab and PLD/carboplatin.
- Trial name
- NCT01837251
- Testing
- Carboplatin, PLD, Bevacizumab
- Where
- 193 sites in Australia, Austria and 4 more
- Volunteers
- 682 people
- Sponsor
- AGO Research GmbH
Endometriosis
Fertility Preservation in Case of Endometriosis
Fertility Preservation is now considered as crucial for the well-being of women battling cancer. However, others indications have more recently emerged.
- Trial name
- PREFENDO (NCT03744754)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
PCOS, Insulin Resistance
Effect of Bromocriptine on Insulin Resistance in Polycystic Ovarian Syndrome - A Pilot Study
The primary aim of this study is to determine the effect of dopamine agonist therapy on insulin resistance in lean vs. obese women with polycystic ovary syndrome.
- Trial name
- PCOS-Pilot (NCT02133755)
- Testing
- Bromocriptine
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- IWK Health Centre
Ovarian Cancer, Cytoreductive Surgery
Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer
The goal of this clinical trial is to learn if intraoperative administration of esketamine would prevent or mitigate postoperative depressive symptoms after cytoreductive surgery in ovarian cancer.
- Conditions
- Ovarian Cancer, Cytoreductive Surgery, Depressive Symptom
- Trial name
- NCT06624878
- Testing
- esketamine
- Where
- China
- Volunteers
- 568 people
- Sponsor
- Zhejiang Cancer Hospital
Stage IV Cancer
Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations
The tolerability of apatinib, an effective antiangiogenic agent, varies greatly in patients with stage IV cancer during treatment.
- Trial name
- NCT03475589
- Testing
- apatinib
- Where
- China
- Volunteers
- 217 people
- Sponsor
- Sun Yat-sen University
Polycystic Ovary Syndrome
The Role of Autoimmunity and Obesity in Polycystic Ovary Syndrome
The goal of the study is to detect autoantibodies in the serum of the women with PCOS and evaluate the obesity markers to investigate the the role of autoimmunity and obesity in PCOS
- Trial name
- NCT05929950
- Where
- Egypt
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sohag University
Ovarian Cancer, Recurrent Ovarian Carcinoma
A New Fast DWI-based MR Protocol for Surveillance in Patients With a High Risk of Ovarian Cancer Recurrence During PARP-inhibitors Maintenance to Enhance Secondary Cytoreduction Results
In ovarian cancer (OC), complete surgical debulking and platinum-based chemotherapy are the standard treatment, now followed by maintenance therapy with PARP inhibitors or Bevacizumab.
- Trial name
- FOFU (NCT06541171)
- Testing
- Magnetic resonance imaging as fpr clinical practice
- Where
- Italy
- Volunteers
- 220 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Hyperandrogenemia, Polycystic Ovary Syndrome
Assessment of Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition
Gonadotropin-releasing hormone (GnRH) is a hormone that regulates the ability of the pituitary to secrete two hormones, luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
- Trial name
- JCM026 (NCT01428245)
- Testing
- Progesterone, Estrace (estrogen)
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Infertility
Protocol to Minimize Injections and Blood Draws for Women Undergoing in Vitro Fertilization
The purpose of the study is to evaluate the safety and efficacy of nasal gonadotropins (Menopur) in women undergoing IVF. The purpose of this study is also to report and monitor any and all side effects of the nasal Menopur.
- Trial name
- NCT02865681
- Testing
- Menopur, Synarel, HCG trigger
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- New Hope Fertility Center
Invasive Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients
This research is looking at the effect of biobehavioral factors such as stress and whether these factors alter how the body responds to chemotherapy, one of the purposes of this study is to determine if the addition of a…
- Conditions
- Invasive Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- NCT01308944
- Testing
- Propranolol
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Polycystic Ovary Syndrome, Hypertension
Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome
Women with androgen excess polycystic ovary syndrome (AE-PCOS) leads to hypertension.
- Trial name
- NCT04327934
- Testing
- GnRH antagonist, GnRH antagonist + MethylTESTOSTERone 5 MG
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Yale University
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and rucaparib camsylate in treating participants with endometrial, ovarian, fallopian tube or primary peritoneal cancer that has come back.
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT03552471
- Testing
- Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, Pharmacokinetic Study
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
This is a Phase 1 study during which patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer will receive investigational study drug MEK162 and paclitaxel.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT01649336
- Testing
- MEK162, MEK inhibitor; oral, Paclitaxel, mitotic inhibitor; intravenous
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Turner's Syndrome
Turner Syndrome: Genotype and Phenotype
This study examines the clinical and genetic factors related to Turner syndrome, a disorder of the sex chromosomes. Humans usually have 23 pairs of chromosomes-thin strands of DNA-in the nucleus of every cell, which contain genes…
- Trial name
- NCT00006334
- Where
- United States
- Volunteers
- 1,017 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Advanced Solid Malignancies
A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies
Fluzoparib is an oral potent, selective PARP-1 and PARP-2 inhibitor. The objective of this study will be to investigate the safety and tolerability of Fluzoparib Capsule when given orally to Chinese patients with advanced solid…
- Trial name
- NCT02575651
- Testing
- Fluzoparib
- Where
- 2 sites in China
- Volunteers
- 79 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.